These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 26264596)

  • 1. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
    Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
    Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
    Yoneda T
    Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
    de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
    Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.
    Perez Ruixo JJ; Doshi S; Sohn W; Chow A
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S85-92. PubMed ID: 25707967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RANKL in breast cancer: bone metastasis and beyond.
    Azim H; Azim HA
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
    Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.